A phase 2 trial published in Nature Medicine shows that teclistamab, a BCMA×CD3 bispecific T-cell engager combined with daratumumab and lenalidomide, achieves deep remissions in newly diagnosed transplant-eligible multiple myeloma with manageable safety. Results support further evaluation as frontline induction therapy. — PDNA transfer via PepFect14 (close-up).jpg by Ivo Kruusamägi / CC BY-SA 4.0 via Wikimedia Commons (CC BY-SA 4.0)
MD, MPH, PhD. Editor-in-Chief, Georgian Medical Journal (GMJ). Professor and Head, School of Public Health, David Tvildiani Medical University (DTMU), Tbilisi, Georgia. Chair, Public Health Institute of Georgia (PHIG). President, Accréditation Sans Frontières (ASF), Paris. Secretary/Treasurer, UEMS Section of Public Health. WHO Consultant, Health and Migration, Geneva. Former Member, UN Secretary-General's Independent Accountability Panel for Every Woman, Every Child, Every Adolescent (IAP-EWEC, 2016–2021). ORCID: 0000-0001-7609-4515.
